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Abstract 31 
Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite 32 
therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in 33 
hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr-Abl mice and 34 
in patients with CML at diagnosis, and Mtss1 was restored when patients achieved complete 35 
remission. Forced expression of Mtss1 decreased clonogenic capacity and motility of murine 36 
myeloid progenitor cells and reduced tumor growth. Viral transduction of Mtss1 into lineage 37 
depleted SCLtTA/Bcr-Abl bone marrow cells decreased leukemic cell burden in recipients, 38 
and leukemogenesis was reduced upon injection of Mtss1 overexpressing murine myeloid 39 
32D cells. Tyrosine kinase inhibitor (TKI) therapy and reversion of Bcr-Abl expression 40 
increased Mtss1 expression but failed to restore it to control levels. CML patient samples 41 
revealed higher DNA methylation of specific Mtss1 promoter CpG sites that contain binding 42 
sites for Kaiso and Rest transcription factors. In summary, we identified a novel tumor 43 
suppressor in CML stem cells that is downregulated by both Bcr-Abl kinase-dependent and -44 
independent mechanisms. Restored Mtss1 expression markedly inhibits primitive leukemic 45 
cell biology in vivo, providing a therapeutic rationale for the Bcr-Abl-Mtss1 axis to target TKI 46 
resistant CML stem cells in patients.  47 
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Introduction 48 
Chronic myeloid leukemia (CML) is a model disease reflecting the biology of a stem cell 49 
driven neoplasm. The reciprocal translocation t(9;22) gives rise to the cytoplasmic Bcr-Abl 50 
protein that activates various signaling pathways resulting in increased proliferation and 51 
differentiation, protection from apoptosis and altered adhesion properties of CML cells1, 2. 52 
Moreover, these cells evolve mechanisms that facilitate disease progression and support 53 
their survival under stressful conditions3, 4. The detection of Bcr-Abl and subsequent 54 
evidence that it is sufficient to induce CML in vivo5 paved the way for the development of 55 
targeted therapy. Today, the implementation of tyrosine kinase inhibitors (TKI) that bind to 56 
and inhibit the Abl kinase has resulted in high molecular response rates6. However, while the 57 
majority of newly diagnosed patients in chronic phase (CP) respond well to TKI treatment, 58 
about one third of the patients develops primary or secondary resistance due to Bcr-Abl 59 
mutations or intolerance to TKIs. Moreover, even in patients without mutations, mechanisms 60 
such as low persisting Bcr-Abl levels in patients on TKI and/or a lack of oncogene addiction 61 
have been described to induce CML stem cell resistance in CP7-9. Genetically, disease 62 
progression is associated with the acquisition of further chromosomal aberrations or 63 
mutations10. At the epigenetic level, DNA promoter methylation of specific genes, often tumor 64 
suppressors, has been associated with disease progression11-13. 65 
The metastasis suppressor 1 (Mtss1) protein has recently been described to exert tumor 66 
suppressive function and its downregulation is associated with poor prognosis in various 67 
cancers 14-19. The structure of the multidomain protein suggests a scaffolding function20, 21, 68 
and Mtss1 was found to interact with multiple partners to regulate actin dynamics and 69 
suppress cell migration and motility in various tumors22-24. The mechanisms that induce these 70 
effects remain poorly understood. 71 
Here, we identified Mtss1 to be suppressed in murine leukemic LSK (lin-;c-kit+;Sca-1+) cells 72 
as well as primary cells from CML patients. Mtss1 downregulation was mediated via Bcr-Abl 73 
kinase dependent and independent mechanisms. Forced expression of the tumor suppressor 74 
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in CML cells reduced leukemic cell growth and motility in vitro and affected malignant cell 75 
propagation and leukemogenesis in vivo.  76 
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Materials and Methods 77 
DNA constructs 78 
Murine Mtss1 cDNA was amplified using cDNA library no. 968, clone IRAVp968D0272D6 79 
(German Resource Center for Genome Research) as a template and the following primer 80 
pair: Mtss1DoEcoRV-AAGATATCCTAAGAGAAGCGCGGTGCTGAGC and 81 
Mtss1UpFlagBamHI-82 
AAAGGATCCATGGACTACAAGGACGACGACGATAAGGAGGCTGTGATCGAGAAGGGAT83 
GCAGCGCGCTTGGAGG. PCR product and pENTRY1A were digested using BamHI and 84 
EcoRV, and positive clones were fully sequenced and shuttled into the pMY destination 85 
vector using LR Clonase (Life Technologies).     86 
 87 
Cell culture 88 
32Dcl3 (here after named 32D) and K562 (ACC-411, ACC-10, DSMZ) cells were cultured as 89 
described previously25. Mononuclear (MNC) cells were cultured in serum-free BIT medium 90 
(Stem Cell Technologies) in the presence of growth factors (5GF) as described previously26. 91 
All applied cell lines were routinely tested for mycoplasma contamination. The application of 92 
primary human samples was approved by the local ethics board of the medical faculty RWTH 93 
Aachen (EK127/12, EK206/09) and by the West of Scotland Research Ethics Service (REC 94 
reference: 15/WS/0077, expiry 05 JUNE 2020). Informed consent was obtained from all 95 
subjects. 96 
 97 
Retroviral transduction  98 
Retroviral transductions were performed as described previously25. Briefly, Plat-E–packaging 99 
cells were transfected with pMY-IRES-GFP (green fluorescent protein) vectors containing the 100 
gene of interest and supernatants were collected after 24h. Virus was centrifuged onto 101 
retronectin-coated 6-well pates, and cells were subsequently added and cultured overnight. 102 
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Transduction was repeated 2 to 3 times on 2 to 3 consecutive days using serum-free 103 
BIT9500 cell culture media (Stem Cell Technologies) that was supplemented with IL3, IL6 104 
and mSCF (10ng/ml, 5ng/ml and 50ng/ml). 105 
 106 
Real-time quantitative RT-PCR (qRT-PCR) 107 
The process of RNA isolation, cDNA synthesis and qRT-PCR have been previously 108 
described27. Commercially available TaqMan assays (Applied Biosystems) were used for 109 
human (HS00207341_m1) or murine Mtss1 (Mm00460614_m1) and murine DNTM3B 110 
(Mm01240113_m1) expression analysis. For human DNMT3B, we used FAM(6-111 
Carboxyfluorescein)-labeled probe #21 from a universal probe library (Roche Diagnostics) 112 
combined with Primer DNMT3BUp-AGTCTGCTAAGCTACACACAGGAC and DNMT3BDo-113 
AAGAGCTTTGGCATGACTGG. 114 
 115 
Migration Assay 116 
Co-culture of 32D and M2-10B4 cells was performed for 16h and time-resolved video 117 
microscopy was subsequently performed for 120min, using a ZEISS microscope Axiovert 118 
40C, linked to a CCD video camera (Hamamatsu). Image acquisition (60s interval for 119 
120min) was controlled by HiPic or WASABI software. Cell contours were segmented with 120 
Amira software and these data served as the basis for the quantification of the migratory 121 
behavior. Migration was quantified as the movement of the cell center with time. We 122 
calculated the cell speed (in µm/min) as a three point difference quotient and the 123 
translocation (in µm) as the net distance covered within the experiment as described 124 
previously28. The directionality was derived from the quotient of translocation and total path 125 
length. 126 
 127 
8 
 
Mice and genotyping 128 
C3H/HeJ mice were purchased from the Jackson Laboratory. Genotyping of SCLtTA/Bcr-Abl 129 
double transgenic (dtg) mice was described previously27. FVB/N CD45.2 recipients were bred 130 
in-house. Animal experiments were approved by the local authorities (Landesamt für Natur, 131 
Umwelt und Verbraucherschutz NRW, LANUV Az. 84-02.04.2013.A072). 132 
 133 
Bone marrow transplantation and cell injection 134 
BM cells were harvested from SCLtTA/BCR-ABL and control mice (SCLtTA stg or wt). Cells 135 
were lineage-depleted using magnetic activated cell sorting (MACS, Miltenyi Biotec) and 136 
infected as described. For transplantation, these cells were injected along with 1x105 FVB/N 137 
CD45.2 spleen cells into irradiated FVB/N CD45.2 mice. Mice were treated with 138 
cotrimoxazole (Ratiopharm) until 2 weeks after transplant. For analysis of tumor formation or 139 
CML development, 32D Bcr-Abl:ev or 32D Bcr-Abl:Mtss1 cells were injected subcutaneously 140 
or intravenously into 3Gy-irradiated or non-irradiated C3H/HeJ mice. Peripheral blood was 141 
collected from the retro-orbital plexus.  142 
 143 
Flow cytometry analysis 144 
PB, BM, and spleen cells were isolated and analyzed as described previously27. In brief, cells 145 
were incubated with CD45.1, CD45.2, and Gr-1 antibodies (BD Biosciences). For LSK cells 146 
we used tricolor labeled CD3, CD4, CD8a, B220, Gr-1 (Caltag/Invitrogen), CD11-b, Ter119 147 
(eBioscience) combined with CD117-APC, Sca-1-biotin and anti-streptavidin-PE-Cy7, (BD 148 
Biosciences) antibodies. FACS was performed using a FACSNavios (Beckman Coulter). 149 
 150 
Methylation analyses 151 
Cells were washed daily and supplemented with 5-aza-2´-deoxycytidine (5-Aza-CdR; Sigma-152 
Aldrich) to a final concentration of 0.2µM for 7 days. For bisulfite sequencing, gDNA was 153 
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isolated using QIAamp DNA Blood Mini Kit (Quiagen) and processed using EZ DNA 154 
Methylation Kit (Zymo Research Corporation) according to the manufacturers´ protocols. The 155 
Mtss1 promoter region was amplified as described29, and processed using Blunting Enzyme 156 
Mix (NEB Inc.), ligated into EcoRV digested pBluescript-KS(+) and sequenced. For each 157 
patient, 9 to 12 single PCR products were analyzed. 158 
 159 
Preparation of cell lysates, SDS–PAGE and immunoblotting 160 
Western blotting was performed as previously described25 and proteins were detected via 161 
chemoluminescence (Fusion SL, PeqLab). 162 
 163 
Colony formation assay 164 
32D cells were mixed with methylcellulose (MethoCult M3231 or M3434 Stem Cell 165 
Technologies) at a density of 200•cells/ml. Colonies were counted 7 days after plating using a 166 
light microscope. 167 
 168 
Motif Matching 169 
We obtained position frequency matrices from Jaspar30. The motif matching procedure was 170 
performed using MOODS31. The threshold corresponded to a p-value of 0.000532. We post-171 
processed all putative binding sites by removing the matches with bit-score log-odds ratio 172 
less than 4, with regard to the corresponding bit-score threshold. 173 
 174 
Chromatin immunoprecipitation (ChiP) 175 
ChIP experiments using KCL-22 cells were performed and analyzed as described 176 
previously19. KAISO (6F8) or REST (H-290) antibody from Santa Cruz Biotechnology and 177 
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following Primers were used: MTSS1-for: ACTACAAGCGGGCTCTGG and MTSS1-rev: 178 
CCCACCCCTACAATGGCTG. 179 
 180 
Statistical analysis 181 
Statistical analyses were performed using Student two-sided t test (normal distribution) or 182 
Mann-Whitney U test (when normal distribution was not given). P<0.05 was considered 183 
statistically significant. The exact sample size (n) represents the number of biological 184 
triplicates and is given in the respective figure legend or in the Results section of the 185 
manuscript. Error bars are given as SEM. Groups with similar variation have been 186 
statistically compared. 187 
 188 
Animal studies 189 
Statistical analyses of data including animal studies were performed as described above. 190 
Blinding or randomization were not applied. Single animals were not excluded from analyses.   191 
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Results 192 
Mtss1 is downregulated in murine and human CML stem cells 193 
We previously developed and applied an inducible double transgenic SCLtTA/Bcr-Abl mouse 194 
model that closely reflects human CML27. Expression profiling using the stem cell enriched 195 
LSK population (GSE18446) revealed a significant 2.35-fold downregulation of the potential 196 
tumor suppressor gene Mtss1. In order to confirm Mtss1 protein downregulation, we 197 
performed Western blot analysis using lineage-depleted BM cells from SCLtTA/Bcr-Abl mice 198 
that had been induced to express Bcr-Abl for four weeks (Figure 1a). We previously 199 
confirmed Bcr-Abl expression in these cells3. Mtss1 protein was completely absent upon Bcr-200 
Abl induction in leukemic lineage-depleted progenitor cells, while 3 of 4 control mice 201 
expressed high levels of Mtss1. Moreover, we confirmed significant 5.8-fold Mtss1 RNA 202 
downregulation in LSK cells using qRT-PCR in a cohort of mice that had expressed Bcr-Abl 203 
for 3 weeks (Figure 1b). Next, we assessed the effect of Bcr-Abl expression on Mtss1 levels 204 
in the murine myeloid progenitor cell line 32D. Again, oncogenic expression dramatically 205 
reduced Mtss1 expression at RNA (Supplementary Figure S1, left) and protein level 206 
(Supplementary Figure S1, right). To study if our data could be translated to human CML, we 207 
performed microarray analyses from publicly available datasets33, 34. These datasets 208 
comprised four Mtss1 probe sets detecting distinct predicted transcripts. First, we checked 209 
for tissue specific expression patterns in the Gene Expression Profiler database35 and out of 210 
the four probe sets, Mtss1_203037_s_at showed highest expression in hematopoietic cells, 211 
including the CD34+CD38- stem cell compartment. Interestingly, this probe set revealed a 212 
significant Mtss1 downregulation in blast cells from newly diagnosed CML patients compared 213 
to healthy donor (HD) CD34+ control samples (Figure 1c, Supplementary Figure S2a). Next, 214 
we performed Western blot analysis using primary MNCs from CML patients. At the time of 215 
diagnosis, Mtss1 protein was absent in all patients (Figure 1d). We then looked at Mtss1 216 
levels in remission samples from two patients: after 9 months of TKI therapy in one patient 217 
(CML01) and 12 months of therapy in another patient (CML02). In CML01 and CML02 Bcr-218 
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Abl levels declined from 47% and 32% to undetectable levels by nested PCR and 0.023%, 219 
respectively. In both patients, Mtss1 was markedly increased during remission. The same 220 
was evident in a third dataset comparing Mtss1 expression at diagnosis (Bcr-Abl expression 221 
77%) and in remission (MR4 and Bcr-Abl not detectable by nested PCR) from two different 222 
CML patients, CML03/04. In line with these data, Mtss1 RNA was also downregulated in 223 
CML patients at diagnosis when compared to healthy control samples (Supplementary 224 
Figure S2b). In another CML patient (CML05) who did not respond to TKI therapy and 225 
developed a T315I mutation, Mtss1 expression was repeatedly absent (Bcr-Abl at diagnosis: 226 
99.61%, +9months: 25.13%). This patient progressed to CML-BC. Absence of Mtss1 protein 227 
was also confirmed in a second CML-BC patient (CML06). This patient relapsed after 228 
allogeneic transplantation and did not respond to TKI therapy. Subsequently a complex 229 
aberrant karyotype was verified in this patient. For samples for which residual RNA was 230 
available, we performed qRT-PCR, including normal controls, which confirmed Mtss1 231 
downregulation in these patients (Supplementary Figure S2c).  232 
 233 
Mtss1 overexpression affects leukemic cell motility, tumor growth and CML 234 
development 235 
To study the potential function of Mtss1 in Bcr-Abl positive hematopoietic cells, we retrovirally 236 
infected 32DBcr-Abl cells using FLAG tagged Mtss1 or empty vector (ev) control retrovirus. 237 
32DBcr-Abl:Mtss1 and 32DBcr-Abl:ev control cells showed no growth differences in 238 
suspension cell culture (data not shown), but CFU (colony forming unit) capacity was 239 
markedly decreased upon Mtss1 overexpression (Figure 2a), in the presence or absence of 240 
added cytokines. This decrease in CFU capacity in 32DBcr-Abl:Mtss1 cells was not due to 241 
Mtss1 induced differentiation. Even in the presence of 40ng/ml G-CSF for 10 days, 32DBcr-242 
Abl:ev or Mtss1 cells did not exceed 2% or 0.5% Gr-1 positivity respectively (Supplementary 243 
Figure S3).  As Mtss1 is involved in cell motility, we next analyzed the capacity of these cells 244 
to migrate upon co-culture using the BM stromal derived cell line M2-10B4. These stromal 245 
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cells had been engineered to overexpress hG-CSF and hIL336. 32DBcr-Abl:ev or 32DBcr-246 
Abl:Mtss1 were seeded on a confluent monolayer, and migration was monitored for up to 247 
120min by means of time-lapse video microscopy. Mtss1 overexpression had a profound 248 
impact on cell motility (Figure 2b). 32DBcr-Abl:ev cells moved with high speed (8.9 ± 2.0 249 
µm/min) and directionality (0.58 ± 0.05) across the stromal cell layer. In contrast, Mtss1-250 
overexpressing cells had a dramatically reduced speed and directionality (1.8 ± 0.2 µm/min 251 
and 0.12 ± 0.02), respectively. To analyze the effect of Mtss1 expression in vivo, we injected 252 
3x105 32DBcr-Abl:ev or 32DBcr-Abl:Mtss1 cells subcutaneously into syngeneic C3H/HeJ 253 
mice after total body irradiation using 3Gy. Mice were sacrificed for analysis 25 days after 254 
injection and tumors that resulted from Mtss1 overexpressing cells were 2.2-fold smaller 255 
compared to ev controls (Supplementary Figure S4a upper panel). We confirmed persisting 256 
Mtss1 overexpression in these tumors via detection of FLAG-tagged Mtss1 protein 257 
(Supplementary Figure S4a lower panel). QRT-PCR capable of detecting transduced and 258 
endogenous Mtss1 confirmed that expression was high in tumors that resulted from 32DBcr-259 
Abl:Mtss1 injection but low in tumors that developed from 32DBcr-Abl:ev cells 260 
(Supplementary Figure S4b). The spleen size of 32DBcr-Abl:Mtss1 injected mice was 1.6-261 
fold decreased compared to controls (Supplementary Figure S4c), but this did not reach 262 
statistical significance. In order to study if Mtss1 overexpression can impair leukemic 263 
development, we next transplanted freshly transduced 32DBcr-Abl:ev or 32DBcr-Abl:Mtss1 264 
cells that express GFP to allow for leukemic cell tracking. 5x105 cells were injected into non-265 
irradiated C3H/HeJ recipients. The disease in this model develops rapidly, and mice were 266 
therefore analyzed 11 days after transplantation. Mtss1 overexpression significantly reduced 267 
the numbers of leukemic cells in PB by 2.8-fold (Figure 2c). Analysis of BM and spleen 268 
confirmed a significant 1.8- and 2.4-fold decrease of leukemic cells in the respective organ, 269 
upon Mtss1 overexpression (Figure 2c). Moreover, splenomegaly was reduced in mice that 270 
had received Mtss1 positive cells (Figure 2d, left). Using an in vivo imaging system (IVIS), we 271 
were able to detect GFP positive leukemic cells in the spleen. These malignant cells were 272 
not evenly spread but clustered in focal areas. Interestingly, overexpression of Mtss1 273 
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decreased leukemic spleen cell burden (Figure 2d, right). We detected reduced Bcr-Abl 274 
expression in BM and spleen of Mtss1 overexpressing cell recipients (Supplementary Figure 275 
S5a). Again, this reflected a decrease in leukemic cell burden, as both cell lines had similar 276 
Bcr-Abl expression levels upon injection (Supplementary Figure S5b). Histology of the spleen 277 
confirmed malignant cell infiltration and this was diminished upon transplantation of Mtss1 278 
overexpressing cells (Supplementary Figure S5c). The decrease in leukemia development 279 
was not due to alterations in the capacity of these cells to home to the BM. However, there 280 
was a 2-fold decrease of cell homing to the spleen, which was not significant suggesting that 281 
Mtss1 overexpression could compromise homing to the vascular niche (Supplementary 282 
Figure S6).  283 
 284 
Mtss1 impairs cell growth of leukemic progenitor cells in vivo 285 
Next, we studied the effect of Mtss1 overexpression using our transgenic SCLtTA/Bcr-Abl 286 
mice that lose Mtss1 protein upon Bcr-Abl expression (Figure 1a). Transduction of 287 
SCLtTA/Bcr-Abl BM allows for differentiation during culture and thus long-term engraftment 288 
of transduced cells is difficult to achieve. Therefore, we used a number of approaches 289 
varying radiation dose, cell numbers and transduction methodology. We repetitively 290 
retrovirally infected lineage negative (lin-) cells from non-induced SCLtTA/Bcr-Abl and control 291 
mice using Mtss1 or ev retrovirus. In vitro CFU assays that were performed in the presence 292 
of cytokines revealed a non-significant 20% decrease in clonogenic potential upon Mtss1 293 
overexpression in these cells (data not shown). In a first in vivo experiment, we transplanted 294 
5x104 FACS-sorted Bcr-Abl negative cells that were infected with Mtss1 or ev (control:Mtss1 295 
and control:ev) as well as 8x104 FACS-sorted Bcr-Abl positive cells, infected with Mtss1 or ev 296 
(Bcr-Abl:Mtss1 and Bcr-Abl:ev) in 6Gy irradiated recipients that did not receive tetracycline to 297 
allow for Bcr-Abl expression in the leukemic cells. PB was drawn 13 days after 298 
transplantation and revealed a significant 1.8-fold decrease of GFP positive cells in 299 
SCLtTA/Bcr-Abl:Mtss1 transplanted recipients compared to SCLtTA/Bcr-Abl:ev controls 300 
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(Supplementary Figure S7). This decrease was accompanied by a reduction of Bcr-Abl 301 
positive Gr1+/GFP+ cells showing that restored Mtss1 expression markedly decreases 302 
leukemic cell propagation in vivo and does not enhance differentiation of myeloid cells. Over 303 
time we lost all GFP positive cells and to increase the number of infected transplanted 304 
transgenic cells, we next avoided sorting and separated donor from wt cells by using CD45.1 305 
(donor) CD45.2 (recipients) strain specific isoform expression (Supplementary Figure S8). 306 
Combined with the retroviral vector encoded GFP expression, this allowed for separation of 307 
infected transgenic cells (CD45.1+/GFP+) from non-infected transgenic cells (CD45.1+/GFP-) 308 
as well as from wt recipient cells (CD45.2+). Transduction efficiency of lin- SCLtTA/Bcr-Abl 309 
BM cells using ev was 70.5% and therefore 1.3-fold higher than Mtss1-transduced BM 310 
(55.3% transduced cells). We injected 3x105 GFP+ cells per recipient that had been irradiated 311 
using 8Gy. Again, the total number of GFP+ cells declined in both groups. However, Mtss1 312 
infected Bcr-Abl cells decreased significantly more rapidly than ev transduced Bcr-Abl cells. 313 
The difference between ev and Mtss1 was 1.3-fold by the time of transduction and increased 314 
to 2.1-fold at day 26 in the PB. Mtss1 overexpression continued to exert a negative effect on 315 
leukemic cell growth as Mtss1 overexpressing cells further declined and were 3.6-fold 316 
decreased in PB on day 78 (Figure 3a). 82 days after transplantation, we sacrificed the 317 
recipients for analysis. There was a significant 3- and 17-fold decrease of Mtss1 318 
overexpressing BM and spleen cells, respectively, as compared to controls (Figure 3b). 319 
Finally, we again infected lin- SCLtTA/Bcr-Abl BM cells using Mtss1 or ev retrovirus and 320 
FACS-sorted GFP+ cells. Western blot analysis confirmed Mtss1 overexpression in 321 
transduced progenitor cells (Figure 3c). For short-term in vivo analysis, we injected 1.3x105 322 
sorted cells into 9Gy-irradiated mice and analyzed these recipients 13 days after 323 
transplantation. Although expression of Bcr-Abl did not differ between the groups 324 
(Supplementary Figure S9), the percentage of Mtss1 overexpressing cells was significantly 325 
diminished in BM, showing a 2.8-fold reduction (Figure 3d), again confirming the adverse 326 
effects of restored Mtss1 expression on leukemic progenitor cell propagation. In vitro 327 
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analysis showed that apoptosis was not increased in total SCLtTA/Bcr-Abl BM cells upon 328 
Mtss1 overexpression (Supplementary Figure S10).  329 
 330 
Mtss1 suppression involves Bcr-Abl kinase activity 331 
As our data demonstrate a tumor suppressing function for Mtss1, we next analyzed if Bcr-Abl 332 
inhibition could completely restore Mtss1 expression levels in vitro and in vivo. Firstly, we 333 
treated 32DBcr-Abl cells as well as 32D control cells with imatinib for 18h and this 334 
significantly increased Mtss1 levels in Bcr-Abl positive, but not negative cells (Figure 4a). 335 
However, treatment could not restore Mtss1 expression to control levels of Bcr-Abl negative 336 
32D cells and this was true despite complete Bcr-Abl kinase inhibition (Supplementary Figure 337 
S11). We then tested Bcr-Abl mediated Mtss1 regulation in human CML and applied imatinib 338 
treatment to K562 cells and this markedly increased Mtss1 expression (Supplementary 339 
Figure S12). Next, we tested Mtss1 expression in primary human MNCs as well as purified 340 
CD34 positive cells. For latter one we previously showed complete Bcr-Abl inhibition upon 341 
16h of imatinib treatment in 5GF26. Upon imatinib and dasatinib treatment both cell types 342 
showed Mtss1 upregulation in response to Bcr-Abl kinase inhibition in 5GF (Supplementary 343 
Figure S13, Figure 4b). To analyze the effect of short-term TKI therapy in vivo, we assessed 344 
Mtss1 levels in BM cells of CML mice that were treated with imatinib for four weeks37 (Figure 345 
4c). Transplantation of SCLtTA/Bcr-Abl BM cells in comparison to Bcr-Abl negative control 346 
cells reduced Mtss1 levels in BM by 13.9-fold in vehicle-treated animals. Imatinib treatment 347 
significantly increased Mtss1 levels in Bcr-Abl positive mice. However, this increase was mild 348 
showing a 3.8-fold rise of transcript level and these mice still had a 3.2-fold Mtss1 reduction 349 
compared to Bcr-Abl negative control animals. We then analyzed Mtss1 expression in 350 
SCLtTA/Bcr-Abl mice that had been reverted for Bcr-Abl expression7 (Figure 4d) and this 351 
confirmed a trend of persisting Mtss1 downregulation upon inhibition of Bcr-Abl kinase 352 
activity for 48 days. These data suggest that Mtss1 suppression might not depend 353 
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exclusively on Bcr-Abl kinase activity and is not mediated via Bcr-Abl kinase independent 354 
mechanisms of the oncogenic protein. 355 
 356 
Mtss1 downregulation is mediated by epigenetic mechanisms    357 
A mechanism that has been described to induce Mtss1 downregulation in cancer is DNA 358 
promoter methylation29, 38. Moreover, the de novo methyltransferase DNMT3B has recently 359 
been shown to be involved in Mtss1 suppression14. We therefore analyzed the potential role 360 
of Mtss1 promoter methylation in CML. Treatment with the demethylating agent 5-Aza-CdR 361 
increased Mtss1 expression by 3.1-fold in 32D-Bcr-Abl, but only 1.5-fold in parental 32D 362 
cells, and 12.1-fold in K562 cells (Figure 5a). Interestingly, TKI treatment decreased 363 
DNMT3B RNA expression in 32D-Bcr-Abl and K562 cells and simultaneously increased 364 
Mtss1 levels, as detected by qRT-PCR (Supplementary Figure S14, Figure 5b). Bisulfite 365 
sequencing of a previously defined Mtss1 promoter region29 confirmed excessive promoter 366 
methylation in K562 cells showing 100% methylation in 24 out of 29 CpG sites and this was 367 
reduced to 8 CpG sites in imatinib and 14 CpG sites in 5-Aza-CdR treated cells 368 
(Supplementary Figure S15). Therefore, we next analyzed Mtss1 promoter methylation using 369 
primary CML cells (n=6) versus normal (n=7). In line with a previous report showing 370 
excessive hypermethylation in cancer cell lines as compared to the primary human 371 
malignancy39, Mtss1 promoter methylation was increased in the CML cell line. Primary CML 372 
samples demonstrated a significant increase in Mtss1 promoter methylation at specific CpG 373 
sites compared to healthy controls (Figure 5c). Sequence based motif analysis indicated two 374 
motifs, REST (Re1-silencing transcription factor) and ZBTB33 (zinc finger and BTB domain 375 
containing 33, also termed KAISO) that match to the region with the highest difference 376 
between the methylation levels of CML and control and both are known to act as 377 
transcriptional repressors. Interestingly, we could confirm binding of both transcription factors 378 
to this Mtss1 promoter region, using ChiP experiments and the human CML cell line KCL-22 379 
(Figure 5d).  380 
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Discussion 381 
Reactivation of tumor suppressors in CML has previously been shown to strongly affect 382 
malignant cell biology and disease progression11, 40-42. Here, we identified Mtss1 to be 383 
downregulated in murine and human leukemic progenitor and stem cells and forced 384 
expression markedly decreases CML cell motility and disease development in vivo. Mtss1 385 
suppression involves DNA promoter methylation in primary CML-CP samples and TKI 386 
therapy in SCLtTA/Bcr-Abl mice only partially restores Mtss1 levels. 387 
Mtss1 has a mutlidomain protein structure that suggests a cytoskeletal associated function20, 388 
21, and both overexpression and knock down of Mtss1 globally impairs cellular architecture, 389 
resulting in altered cell motility, adhesion, and/or proliferation in normal and malignant cells22-390 
24. Mtss1 function appears to depend on the cell type or context as it acts as a tumor 391 
suppressor14, 43, 44 but also exerts oncogenic effects45.  392 
Our data reveal that, while Mtss1 expression did not affect proliferation in pure suspension 393 
cell cultures, overexpression markedly decreased the clonogenic potential and cell motility of 394 
CML cells. Moreover, Mtss1 overexpression reduced leukemic progenitor cell growth and 395 
CML development in vivo. Decreased cell motility and reduced in vivo proliferation upon 396 
Mtss1 overexpression have also been described in a breast cancer mouse model46. In 397 
hepatocellular carcinoma (HCC), Mtss1 overexpression decreased the proliferation and 398 
clonogenic potential, while Mtss1 knockdown increased tumor formation in vivo14. The tumor 399 
suppressive function of Mtss1 involves an altered bidirectional communication between the 400 
cell and its tumor niche. Using a mouse model of targeted Mtss1 disruption, Yu et al. 401 
demonstrated a predisposition for lymphoma development in aging mice43. These mice 402 
showed an altered B-cell differentiation potential and a pathologic communication between 403 
B-cells and their microenvironment, with Mtss1 knockout cells failing to internalize the 404 
chemokine receptor CXCR5 upon exposure to its ligand, CXCL13, a chemokine released 405 
from splenic stromal cells43. CML cells are characterized by a premature release into the 406 
blood and this can be mediated via altered chemotaxis, e.g. via CXCR4 expression, or 407 
altered cell interaction with extracellular matrix proteins involving integrins, selectins or 408 
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cadherins2, 47. In CML, adhesion mediated suppression of proliferation is impaired48 and 409 
taken together it is conceivable if not likely that Mtss1 overexpression inhibits colony growth, 410 
cellular migration and subcutaneous tumor growth in response to cell-cell or cell-matrix 411 
interaction. However, the mechanism of how Mtss1 expression increases adhesion and 412 
reduces growth of malignant cells remains to be clarified. 413 
In a breast cancer mouse model, Mtss1 overexpression impaired cell migration and reduced 414 
metastasis via inactivation of the small GTPase RhoA46. Interestingly, RhoA is activated in 415 
Bcr-Abl positive cells and mediates transformation in vivo49. GTPases have been shown to 416 
regulate homing and mobility of normal and malignant HSC50, 51. In an in vitro model of breast 417 
cancer, Mtss1 loss enhanced cell invasion, and this involved upregulation of the tyrosine 418 
phosphatase PTP´  and subsequent Src activation by dephosphorylating an inhibitory Src-419 
kinase phosphotyrosine residue52. Interestingly, phosphorylation of Src-kinase Lyn at the 420 
activating phosphotyrosine residue facilitates the imatinib-induced migration of CML cells to 421 
the BM53. 422 
As forced Mtss1 expression reduced the leukemic potential of primitive CML cells, as 423 
demonstrated in this study, it would be extremely interesting to investigate the therapeutic 424 
potential of preventing or reversing Mtss1 suppression in combination with TKI therapy in the 425 
future. Mtss1 has previously been described to be activated by Sonic Hedgehog (Shh) 426 
signalling and can subsequently associate with Gli transcription factors to potentiate Shh 427 
signalling 54. Our own confocal microscopy data revealed that Mtss1 localization was 428 
restricted to the cytoplasm (Supplementary Figure S16) suggesting that Mtss1 does not 429 
associate with Gli in our model. Bcr-Abl inhibition did not increase expression of the Shh 430 
target gene Gli1 in K562 cells (data not shown) suggesting that TKI induced upregulation of 431 
Mtss1 did not enhance Shh signalling. However, conversely we did observe that IM-induced 432 
upregulation of Mtss1 expression was impaired by simultaneous Shh inhibition 433 
(Supplementary Figure 17) which implies that Shh signalling is involved in Mtss1 gene 434 
regulation. The mechanisms that induce inactivation of tumor suppressors in CML vary and 435 
include binding of inhibitory proteins and/or enhanced protein degradation40, 55 as well as 436 
20 
 
downregulation by genetic or epigenetic mechanisms41. DNA promoter methylation of tumor 437 
suppressor genes has been described to occur upon CML progression11-13, but it also already 438 
exists in CML-CP. Interestingly, the adhesion promoting molecule Cadherin 13 has been 439 
shown to be downregulated via DNA promoter methylation in CML-CP and this correlated 440 
with poor response to treatment56. Our data reveal DNA methylation of the Mtss1 promoter in 441 
CML-CP patients at the time of diagnosis. It has been described that DNMT3B is responsible 442 
for Mtss1 suppression in HCC14, and here we show that DNMT3B expression was inversely 443 
correlated with Mtss1 expression in treatment-naïve cells as well as after TKI treatment, 444 
suggesting that DNMT3B is involved in Mtss1 downregulation in CML cells. Likewise, 445 
suppression of Mtss1 by DNA methylation has also been described for bladder and gastric 446 
cancer29, 38. Along the same line, we previously demonstrated Mtss1 suppression in FLT3-447 
ITD positive AML and low Mtss1 expression correlated with high DNMT3B levels in primary 448 
AML samples, suggesting that Mtss1 suppression could be a common mechanism in 449 
oncogenic tyrosine kinase induced leukemia19.  450 
In a phase II clinical trial, 63% of CML-CP patients had objective responses to 5-Aza-CdR 451 
(decitabine) demethylating therapy, as well as 55% in CML-AP and 28% in CML-BC57. The 452 
potency of demethylating agents varies and in line with this clinical trial, we used 5-Aza-CdR 453 
for our studies that has previously been shown to be more potent than 5-Azacytidine58. 454 
Clinical trials elucidating the role of TKI therapy combined with decitabine have been 455 
performed for imatinib-refractory CML-AP and CML-BC but did not show improved 456 
responses as compared to decitabine alone59. Our data demonstrate methylation of the 457 
Mtss1 promoter already in CML-CP patients providing a rationale to further explore the 458 
therapeutic benefit of demethylation agents combined with TKI therapy in early phase CML. 459 
In addition to decitabine, exploration of more specific DNMT3B inhibitors, such as 460 
nanaomycin A, is in progress60. Nanaomycin A is an antibiotic belonging to the antracycline 461 
group and similar compounds such as doxorubicin or daunomycin have been shown to exert 462 
powerful antitumor activity. 463 
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The exact mechanism on how Mtss1 promoter methylation results in decreased expression 464 
needs to be clarified. However, we identified increased methylation in specific CpG sites in 465 
CML, and these CpG sites harbor transcription factor binding sites for KAISO and REST, two 466 
transcriptional repressors. Like BCL-6 or PLZF, KAISO is a member of POZ-ZF transcription 467 
factors that are involved in the process of cancer development and CML stem cell survival61. 468 
Interestingly, KAISO preferentially binds to methylated DNA to enable recruitment of the 469 
histone deacetylase-containing nuclear corepressor complex (NCoR) that enhances 470 
chromatin condensation and therefore gene silencing62. In CML, KAISO expression has 471 
solely been described in the context of a CML-BC cell line model, and here, KAISO 472 
inactivation reduced granulocytic differentiation by suppression of CEBPalpha63. 473 
Despite the described biochemical characteristics of the Mtss1 protein, its role in different 474 
tissues is only poorly understood. Here, we demonstrate that Mtss1 functions as a tumor 475 
suppressor in CML, providing a rationale for enhancing Mtss1 expression in CML in order to 476 
target the TKI resistant stem cell population.  477 
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Figure Legends 766 
Figure 1: Mtss1 is suppressed in CML stem cells. a) Lineage negative BM cells from 767 
control mice and from SCLtTA/Bcr-Abl that had been induced to express Bcr-Abl for four 768 
weeks were isolated using magnetic bead cell sorting. Protein lysates from these cells were 769 
analyzed for Mtss1 by Western blot (n= 4/4). b) LSK cells were isolated via FACS from 770 
induced SCLtTA/Bcr-Abl and control mice. Expression of Mtss1 was assessed by qRT-PCR 771 
and is shown as percent of GAP-DH (n=3/3). c) RNA expression of Mtss1 in normal healthy 772 
donor (HD) CD34 positive cells (n=74) and CML blasts in chronic phase (n=76; GSE#4170). 773 
d) Mtss1 levels determined by Western blot in CML-CP patients’ blood mononuclear cells at 774 
diagnosis and in complete hematologic remission (upper panel) versus CML-BC (lower 775 
panel). 776 
Figure 2: Mtss1 overexpression affects leukemic cell motility, solid tumor growth and 777 
CML development. a) 200 cells were seeded in methylcellulose containing cytokines (IL3, 778 
IL6 and mSCF) or no cytokines. Numbers of CFU were counted after 7 days of culture 779 
(n=3/3). b) Migration of individual cells was tracked for up to 120min (upper panel) and 780 
shown are the mean values of speed (lower left) and directionality (lower right) from 781 
individual cells each in three independent experiments. Cell motility was analyzed using 782 
Amira® software, n 32DBcr-Abl:ev=27, n 32DBcr-Abl:Mtss1=31. c) C3H/HeJ mice were 783 
transplanted using 32DBcr-Abl:ev or 32DBcr-Abl:Mtss1 cells (n=5/5). PB, BM and spleen 784 
cells were subjected to flow cytometry analysis 11 days after transplantation. d) Spleen size 785 
of 32DBcr-Abl:Mtss1 and 32DBcr-Abl:ev transplanted recipients (left) and leukemic cell 786 
burden analysis in spleen by IVIS imagine systems detecting fluorescing (GFP positive) 787 
leukemic cells (right). *p<0.05, ***p<0.001 788 
Figure 3: Mtss1 impairs leukemic progenitor cell growth in vivo. a) PB was analyzed by 789 
flow cytometry for GFP positive cells 26 and 78 days after transplantation of 3x105 790 
GFP/CD45.1+ cells that had been transduced to express Mtss1 or ev control (n=8/8). b) BM 791 
and spleen cells were analyzed at autopsy 82 days after transplantation. c) Expression of 792 
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Mtss1 was confirmed by Western blot using protein lysates from infected, sorted lineage 793 
negative BM cells. d) Percent of GFP positive cells was analyzed in BM and spleen 13 days 794 
after transplantation, in recipients of 1.3x105 FACS-sorted SCLtTA/Bcr-Abl:ev or 795 
SCLtTA/Bcr-Abl:Mtss1 cells (n=3/4). *p<0.05, **p<0.01 796 
Figure 4: Suppression of Mtss1 is mediated via Bcr-Abl activity. a) 32D and 32DBcr-Abl 797 
cells were subjected to imatinib (IM 5µM) treatment for 18h, and Mtss1 expression was 798 
assessed by qRT-PCR (n=3/3). b) CD34 positive cells from CML patients at diagnosis (n=3) 799 
were treated with imatinib (5µM, n=3) or dasatinib (Da 150nM, n=3) for 24h. Mtss1 levels 800 
were assessed by qRT-PCR. c) Recipients of SCLtTA/Bcr-Abl or control BM cells were 801 
treated with imatinib or vehicle control for four weeks27 and Mtss1 expression was assessed 802 
in isolated BM cells (n=3/3). d) Expression of Mtss1 in SCLtTA/Bcr-Abl and control mice 803 
upon 25 days of induction (n=3/3) and after reversion (n=4/4) of Bcr-Abl expression for 48 804 
days. *p<0.05; **p<0.01    805 
Figure 5: Mtss1 is downregulated via DNA promoter methylation. a) 32D, 32DBcr-Abl 806 
(B/A) and K562 cells were subjected to 0.2µM 5-aza-2´-deoxycytidine (5-Aza-CdR) treatment 807 
and Mtss1 expression was determined at the indicated time points (n=3/3). b) Mtss1 and 808 
DNMT3B expression were analyzed in imatinib treated K562 cells (18h, 5µM) by qRT-PCR 809 
and are shown as % of GAP-DH (n=3/3). c) Genomic DNA isolated from PB-derived cells of 810 
six CML patients at diagnosis and seven healthy controls was isolated and analysed for 811 
Mtss1 promoter methylation using bisulfite sequencing (n=6/7). d) ChIP for KAISO and Rest 812 
binding to the Mtss1 promoter region was performed using KCL-22 cell line (n=3/3). *p<0.05; 813 
**p<0.01; ***p<0.001 814 






















